2025; 1-1 | pp.26-29

Academians Journal of Natural and Biosciences Studies

ISSN: XXXX-XXXX

Volume 1, Issue 1, July-September 2025

(An Academians Publishers of Research & Academic Resources)

Original Research Article

Received: 18-07-2025 **Accepted**: 28-08-2025 **Published**: 30-09-2025

Physiological Effects of Liver Cirrhosis on Abdominal Adipose Tissue

Ahmed Jabbar Obaid[1]

[1]*Department of Applied Pathological Analysis , College of Science ,Al-Nahrain University,Iraq.*

Email : ahmed.jabbar@nahrainuniv.edu.iq

Abstract: Liver cirrhosis, a progressive and irreversible condition marked by hepatic fibrosis and architectural distortion of the liver, exerts profound physiological effects on peripheral metabolic tissues, including abdominal fat cells. Visceral adipose tissue (VAT) plays an active role in systemic metabolism and communicates bidirectionally with the liver through adipokines and free fatty acids (FFAs). In cirrhosis, metabolic dysregulation—characterized by insulin resistance, chronic inflammation, and altered adipokine secretion—disrupts normal adipocyte function. This results in enhanced lipolysis, increased circulating FFAs, and an inflammatory adipose microenvironment, all of which contribute to hepatic fat accumulation and fibrogenesis. Key adipokines such as leptin and adiponectin become dysregulated, further influencing hepatic stellate cell activation and promoting fibrotic progression. Additionally, portal hypertension and nutritional deficiencies associated with cirrhosis exacerbate adipose tissue remodeling and lead to fat wasting and sarcopenia. Understanding the pathophysiological interplay between cirrhotic liver changes and abdominal fat cell function is crucial for identifying novel metabolic targets in the treatment and management of advanced liver disease.

Keywords: *Liver Cirrhosis, Abdominal Fat Cells, Visceral Adipose Tissue (VAT), Hepatic Fibrosis.*

1. Independent Scholar

Introduction

Liver cirrhosis, the end-stage manifestation of chronic hepatic injury characterized by fibrosis, loss of functional hepatocytes, and progressive portal hypertension, profoundly alters systemic metabolic homeostasis. Among the affected tissues, abdominal (particularly visceral) adipose tissue plays a pivotal role in the progression and severity of cirrhosis via endocrine and metabolic signaling pathways. Visceral adipose tissue is metabolically distinct from subcutaneous fat—not only storing energy as triglycerides but also secreting bioactive adipokines and cytokines such as leptin, adiponectin, resistin, IL-6, and TNF-α. In cirrhosis, the profile of these adipokines shifts significantly: adiponectin, normally protective and anti-fibrotic, may be dysregulated, while leptin, which can promote hepatic stellate cell activation and fibrosis, tends to exert profibrogenic effects. Moreover, cirrhosis is commonly associated with insulin resistance and hyperinsulinemia, which disturb the normal regulation of lipolysis in white adipose tissue. Loss of insulin's inhibitory control leads to excessive free fatty acid (FFA)

Available Online:

*Corresponding Author: Ahmed Jabbar Obaid

release from abdominal fat stores. These FFAs, via the portal circulation, promote hepatic fat accumulation, contribute to steatosis, inflammation, and ultimately exacerbate liver pathology. Simultaneously, portal hypertension and malnutrition in cirrhotic individuals often precipitate wasting of adipose and lean tissue mass. Transjugular intrahepatic portosystemic shunts (TIPS)—a procedure to alleviate portal pressure—can result in weight gain, increased fat-free mass, and even improved muscle strength, suggesting that hemodynamic alterations substantially influence adipose tissue dynamics. Finally, visceral fat volume itself correlates with liver inflammation and fibrosis severity—independent of insulin resistance and total adiposity. Each incremental increase in intra-abdominal fat raises the risk for worsening steatohepatitis or fibrosis, with elevated IL-6 levels serving as an inflammatory biomarker linked to both adipose and hepatic pathology.

Methodology

Patient cohort and imaging: Studies of patients with cirrhosis stratified by Child–Pugh class underwent CT assessment to determine visceral adipose tissue (VAT) vs. subcutaneous adipose tissue (SAT) distribution. Visceral-to-subcutaneous ratio (VSR) served as the index of redistribution in advanced disease versus controls.

Insulin resistance protocols: In related studies of chronic liver disease (e.g., HCV-associated fibrosis), researchers measured adipose tissue-specific insulin resistance (Adipo-IR = FFA × insulin) and systemic HOMA-IR, coupled with metabolomic/lipidomic profiling via chromatography–mass spectrometry.

In vitro/ex vivo lipolysis assays: Visceral and subcutaneous fat biopsies from obese individuals were exposed to lipolytic stimuli (e.g., noradrenaline), quantifying glycerol and free fatty acid release to assess depot-specific lipolytic responsiveness.

Adipokine analysis: Serum and tissue expression of adipokines including leptin, adiponectin, resistin, visfatin and inflammatory cytokines such as TNF-α and IL-6 were measured in cirrhotic patients versus controls, and correlated with fibrosis and metabolic markers.

Results

Visceral fat redistribution: Patients with Child–Pugh class C cirrhosis showed significantly elevated VSR compared to less advanced disease, independent of BMI; BMI poorly correlated with VAT fraction [10].

Adipose insulin resistance and fibrosis severity: In CLD/HCV cohorts, increased Adipo-IR was tightly associated with higher stages of liver fibrosis (F3–F4), and with specific lipidomic changes such as altered ceramides and lysophosphatidylcholine levels.

Depot-specific lipolysis: Visceral adipocytes from subjects with high hepatic fat content exhibited roughly double the maximal glycerol and FFA release in response to lipolytic agents compared to SAT, indicating augmented visceral lipolysis linked with liver fat accumulation.

Adipokine alterations: Cirrhotic patients revealed dysregulated adipokine profiles: elevated leptin and pro-inflammatory cytokines promoted fibrogenic signaling, while adiponectin decreased in advanced disease; visfatin levels varied depending on etiology but generally linked to hepatic inflammation and HSC activation.

Discussion

Mechanistic link between VAT and hepatic pathology: Enhanced lipolysis in visceral fat releases FFAs via portal circulation, directly fueling hepatic steatosis and fibrogenic cascades in cirrhosis—consistent with "portal overflow" and "lipotoxicity" hypotheses [9].

Insulin resistance and altered metabolism in adipose tissue: Elevated Adipo-IR reflects adipose tissue's inability to suppress lipolysis under insulin, feeding into systemic and hepatic metabolic derangement. Lipidomic

Available Online:

biomarkers further correlate with advanced fibrosis stages.

Adipocytokine-mediated hepatic stellate cell (HSC) activation: Leptin enhances HSC activation, proliferation, and persistence of fibrogenic matrix, while adiponectin inhibits these processes via pro-apoptotic and matrix-degrading pathways; imbalance accelerates fibrosis in cirrhosis.

Redistribution of adipose depots despite stable BMI: Visceral adiposity increases in advanced cirrhosis even without total fat gain, indicating selective hypertrophy and preferential VAT deposition amid systemic inflammation and altered metabolic signaling.

Visfatin complexities: Circulating visfatin presents mixed findings—some reports show decreased levels in general cirrhosis, while in HBV-related disease, elevated visfatin promotes inflammation and fibrogenesis through HSC stimulation.

Conclusion

Advanced liver cirrhosis elicits significant physiological changes in abdominal adipose tissue: visceral fat undergoes preferential hypertrophy; visceral adipocytes become insulin-resistant and hyper-lipolytic, leading to increased FFA delivery to the liver; adipokine dysregulation further amplifies hepatic inflammation and fibrosis via direct effects on stellate cells. These inter-tissue interactions create a vicious cycle of metabolic dysfunction and progressive liver damage.

Recommendations

1. **Clinical monitoring**: Use imaging-based indices such as VSR (via CT/MRI) rather than BMI to assess adipose distribution in cirrhotic patients.
2. **Therapeutic targeting of adipose dysfunction**:
    - Interventions aimed at reducing visceral adipocyte lipolysis (e.g., pharmacological modulation of lipolytic signaling or hepatokines like Activin E) may mitigate hepatic fat burden.
    - Strategies to rebalance adipokine profiles—enhancing adiponectin activity or inhibiting leptin/visfatin signaling—might slow fibrogenesis.
3. **Metabolomic biomarkers**: Adipo-IR, ceramide species, and lysophosphatidylcholine levels may serve as non-invasive markers of fibrosis severity and metabolic risk in chronic liver disease.
4. **Holistic metabolic management**: Integrated approaches addressing nutrition, insulin sensitivity, inflammation, and gut-liver-adipose axis signaling should be prioritized in cirrhosis care.

References

McCormick, P. A., & Jalan, R. (2018). Chapter 8: Hepatic cirrhosis. In J. S. Dooley, A. S. Lok, G. Garcia-Tsao, & M. Pinzani (Eds.), *Sherlock's diseases of the liver and biliary system* (13th ed., pp. 107–126). Wiley Blackwell.

Saxena, N. K., & Anania, F. A. (2015). Adipocytokines and hepatic fibrosis. *Trends in Endocrinology & Metabolism, 26*(3), 153–161. https://doi.org/10.1016/j.tem.2015.01.002

Buechler, C., Haberl, E. M., Rein-Fischboeck, L., & Aslanidis, C. (2017). Adipokines in liver cirrhosis. *International Journal of Molecular Sciences, 18*(7), 1392. https://doi.org/10.3390/ijms18071392

van der Poorten, D., Milner, K. L., Hui, J., Hodge, A., Trenell, M. I., Kench, J. G., London, R., Peduto, T., Chisholm, D. J., & George, J. (2008). Visceral fat: A key mediator of steatohepatitis in metabolic liver disease. *Hepatology, 48*(2), 449–457. https://doi.org/10.1002/hep.22350

Sharma, R., Schluger, A., Ahmed, F. S., Nobel, Y. R., Guo, X., Zhao, B., & Verna, E. C. (2023). Visceral adiposity in cirrhosis: Association with disease severity and impact of liver transplantation. *Hepatology Communications, 7*(6), e0113. https://doi.org/10.1002/hep4.0113

Gaggini, M., Carli, F., Rosso, C., Younes, R., D'Aurizio, R., Bugianesi, E., & Gastaldelli, A. (2019). Altered metabolic profile and adipocyte insulin resistance mark severe liver fibrosis in patients with chronic liver disease. *International Journal of Molecular Sciences, 20*(24), 6333. https://doi.org/10.3390/ijms20246333

Thörne, A., Löfgren, P., & Hoffstedt, J. (2010). Increased visceral adipocyte lipolysis—A pathogenic role in nonalcoholic fatty liver disease? *Journal of Clinical Endocrinology & Metabolism, 95*(10), E209–E213. https://doi.org/10.1210/jc.2010-0520

Gaggini, M., Carli, F., Rosso, C., Younes, R., D'Aurizio, R., Bugianesi, E., & Gastaldelli, A. (2019). Altered metabolic profile and adipocyte insulin resistance mark severe liver fibrosis in patients with chronic liver disease. *International Journal of Molecular Sciences, 20*(24), 6333. https://doi.org/10.3390/ijms20246333

Buechler, C., Haberl, E. M., Rein-Fischboeck, L., & Aslanidis, C. (2017). Adipokines in liver cirrhosis. *International Journal of Molecular Sciences, 18*(7), 1392. https://doi.org/10.3390/ijms18071392

Saxena, N. K., & Anania, F. A. (2015). Adipocytokines and hepatic fibrosis. *Trends in Endocrinology & Metabolism, 26*(3), 153–161. https://doi.org/10.1016/j.tem.2015.01.00